Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2020 00:09 ET | Source: TLC

TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
February 12, 2020 04:00 ET | Source: TLC

TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
January 08, 2020 04:00 ET | Source: TLC

TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy

Part 2 will dose ~150 patients with TLC590, bupivacaine, or placeboPrimary endpoint: AUC0-72 on numerical pain rating scaleEnrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA...
October 21, 2019 05:24 ET | Source: TLC

TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
March 25, 2019 05:00 ET | Source: TLC

TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019

SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
March 11, 2019 06:27 ET | Source: Taiwan Liposome Company, Ltd.

TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain

TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
August 14, 2018 04:55 ET | Source: Taiwan Liposome Company, Ltd.

TLC Doses First Patients in Phase I/II Trial of TLC590 for Postsurgical Pain Management

TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the...